Provectus Biopharmaceutica Shares Outstanding vs. Total Debt

PVCTDelisted Stock  USD 0.11  0.00  0.00%   
Based on the key profitability measurements obtained from Provectus Biopharmaceutica's financial statements, Provectus Biopharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Provectus Biopharmaceutica's ability to earn profits and add value for shareholders.
For Provectus Biopharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Provectus Biopharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Provectus Biopharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Provectus Biopharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Provectus Biopharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Please note, there is a significant difference between Provectus Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Provectus Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Provectus Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Provectus Biopharmaceutica Total Debt vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Provectus Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Provectus Biopharmaceutica value to that of its competitors to determine the firm's financial worth.
Provectus Biopharmaceuticals is considered to be number one stock in shares outstanding category among its peers. It is rated below average in total debt category among its peers making up about  0.01  of Total Debt per Shares Outstanding. The ratio of Shares Outstanding to Total Debt for Provectus Biopharmaceuticals is roughly  183.21 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Provectus Biopharmaceutica's earnings, one of the primary drivers of an investment's value.

Provectus Total Debt vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Provectus Biopharmaceutica

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
419.55 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Provectus Biopharmaceutica

Total Debt

 = 

Bonds

+

Notes

 = 
2.29 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Provectus Total Debt vs Competition

Provectus Biopharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 822.62 Million. Provectus Biopharmaceutica adds roughly 2.29 Million in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Valuation  Workforce  Capitalization  Revenue

Provectus Biopharmaceutica Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Provectus Biopharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Provectus Biopharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Provectus Biopharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Provectus Biopharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.

Provectus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Provectus Biopharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Provectus Biopharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Provectus Biopharmaceutica's important profitability drivers and their relationship over time.

Use Provectus Biopharmaceutica in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Provectus Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Provectus Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.

Provectus Biopharmaceutica Pair Trading

Provectus Biopharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Provectus Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Provectus Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Provectus Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Provectus Biopharmaceuticals to buy it.
The correlation of Provectus Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Provectus Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Provectus Biopharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Provectus Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Provectus Biopharmaceutica position

In addition to having Provectus Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Value Funds Thematic Idea Now

Large Value Funds
Large Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Provectus OTC Stock

If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Transaction History
View history of all your transactions and understand their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies